Can Definitive Healthcare Corp. (DH) Maintain Stability After Revised Price Target From Baird?

We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Definitive Healthcare Corp. is among the best penny stocks on this list.

TheFly reported on May 8 that Baird reduced its price target on DH to $1.10 from $1.30 in a revised outlook, while a Neutral rating was maintained. The adjustment came after the firm refreshed its financial model in response to the company’s first-quarter performance.

On May 7, Definitive Healthcare Corp. released its first-quarter 2026 results for the period ended March 31, 2026, reporting revenue of $55.9 million, down 6% from $59.2 million a year earlier. The company recorded a net loss of $192.4 million, which included significant goodwill impairment charges, compared with a $155.1 million loss in the prior-year quarter.

Can Definitive Healthcare Corp. (DH) Maintain Stability After Revised Price Target From Baird?

The company’s Adjusted profitability showed improvement, with adjusted net income of $8.5 million versus $7.0 million, and adjusted EBITDA rising to $15.3 million, or 27% of revenue, compared with $14.7 million and 25% previously. Cash flow from operations reached $11.6 million, while unlevered free cash flow totaled $18.0 million. Looking ahead, the business issued second-quarter and full-year 2026 guidance, projecting stable revenue trends alongside continued adjusted profitability and EBITDA margin expansion supported by operating efficiency and disciplined cost management.

Definitive Healthcare Corp. is a SaaS healthcare data company based in Framingham. It provides analytics on healthcare providers and claims to help clients improve sales, marketing, and market research.

READ NEXT: 8 Most Oversold Large Cap Stocks to Buy and 10 Best Cancer Stocks to Buy for the Long Term. 

Follow Insider Monkey on Google News.